Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer

Molecular Pharmacology

Volumn 76, Issue 5, 2009, Pages 969-983

  Ito, Emma ^a,b   Yip, Kenneth W ^c   Katz, David ^a,b   Fonseca, Sonali B ^d   Hedley, David W ^a,b   Chow, Sue ^a,b   Xu, G Wei ^a,b   Wood, Tabitha E ^a,b   Bastianutto, Carlo ^a,b   Schimmer, Aaron D ^a,b   Kelley, Shana O ^a,d   Liu, Fei Fei ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOPTOSIS INDUCING FACTOR; CASPASE; CETRIMIDE; CISPLATIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL MEMBRANE DEPOLARIZATION; CELL POPULATION; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GAMMA RADIATION; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CETRIMONIUM COMPOUNDS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350462567     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.055277     Document Type: Article

References (50)

1. Agarwala SS, Cano E, Heron DE, Johnson J, Myers E, Sandulache V, Bahri S, Ferris R, Wang Y, and Argiris A (2007) Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 18:1224-1229. (Pubitemid 47244370)
2. Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB, Knowles S, Bell JC, Busson P, Takada K, et al. (2008) Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res 14:4891-4897.
3. Bârzu O, Guerrieri F, Scarfò R, Capozza G, and Papa S (1989) Effect of cetyltrimethylammonium on ATP hydrolysis and proton translocation in the F0-F1 H+-ATP synthase of mitochondria. J Bioenerg Biomembr 21:403-414.
4. Bleday R, Weiss MJ, Salem RR, Wilson RE, Chen LB, and Steele G Jr (1986) Inhibition of rat colon tumor isograft growth with dequalinium chloride. Arch Surg 121:1272-1275. (Pubitemid 17180512)
5. Breen L, Heenan M, Amberger-Murphy V, and Clynes M (2007) Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. Anticancer Res 27:1361-1364. (Pubitemid 46807283)
6. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501. (Pubitemid 28538613)
7. Capaldi RA and Aggeler R (2002) Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor. Trends Biochem Sci 27:154-160.
8. Chen LB (1988) Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155-181.
9. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, and Lee JC (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83:121-126. (Pubitemid 29409487)
10. Cohen NA, Lai SY, Ziober AF, and Ziober BL (2004) Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope 114:418-423. (Pubitemid 38391902)
11. Dairkee SH and Hackett AJ (1991) Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue. Breast Cancer Res Treat 18:57-61.
12. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253. (Pubitemid 36025246)
13. Davis S, Weiss MJ, Wong JR, Lampidis TJ, and Chen LB (1985) Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260:13844-13850. (Pubitemid 16233244)
14. Fantin VR and Leder P (2006) Mitochondriotoxic compounds for cancer therapy. Oncogene 25:4787-4797.
15. Ferri KF and Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nat Cell Biol 3:E255-E263.
16. Gilchrist DS (1979) Chemical peritonitis after cetrimide washout in hydatid-cyst surgery. Lancet 2:1374.
17. Giraud I, Rapp M, Maurizis JC, and Madelmont JC (2002) Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma. J Med Chem 45:2116-2119. (Pubitemid 34477724)
18. Green DR and Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629.
19. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, and Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151-157. (Pubitemid 27303173)
20. Heerdt BG, Houston MA, and Augenlicht LH (2005) The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res 65:9861-9867.
21. Inman JK (1982) Cetrimide allergy presenting as suspected non-accidental injury. Br Med J (Clin Res Ed) 284:385. (Pubitemid 12171697)
22. Isa AY, Ward TH, West CM, Slevin NJ, and Homer JJ (2006) Hypoxia in head and neck cancer. Br J Radiol 79:791-798.
23. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
24. Kroemer G (2006) Mitochondria in cancer. Oncogene 25:4630-4632.
25. Kundu M and Thompson CB (2005) Macroautophagy versus mitochondrial autophagy: a question of fate? Cell Death Differ 12 (Suppl 2):1484-1489. (Pubitemid 41553984)
26. Lo KW, To KF, and Huang DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5:423-428.
27. Modica-Napolitano JS and Aprille JR (1987) Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 47:4361-4365.
28. Modica-Napolitano JS, Brunelli BT, Koya K, and Chen LB (1998) Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077. Cancer Res 58:71-75. (Pubitemid 28027719)
29. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, and Chen LB (1996) Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 56:544-550. (Pubitemid 26048604)
30. Momoi T (2004) Caspases involved in ER stress-mediated cell death. J Chem Neuroanat 28:101-105. (Pubitemid 39195255)
31. Pang S and Willis L (1997) Final report on the safety assessment of cetrimonium chloride, cetrimonium bromide, and steartrimonium chloride. Int J Toxicol 16: 195-220. (Pubitemid 27306455)
32. Parkin DM, Bray F, Ferlay J, and Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156. (Pubitemid 32911406)
33. Petersen C, Zips D, Krause M, Völkel W, Thames HD, and Baumann M (2005) Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 74:331-336. (Pubitemid 40349144)
34. Robey IF, Lien AD, Welsh SJ, Baggett BK, and Gillies RJ (2005) Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7:324-330.
35. Rosenthal DI, Lewin JS, and Eisbruch A (2006) Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24:2636-2643. (Pubitemid 46622085)
36. Schimmer AD, Hedley DW, Chow S, Pham NA, Chakrabartty A, Bouchard D, Mak TW, Trus MR, and Minden MD (2001) The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ 8:725-733. (Pubitemid 32685170)
37. Scorrano L, Petronilli V, and Bernardi P (1997) On the voltage dependence of the mitochondrial permeability transition pore. A critical appraisal. J Biol Chem 272:12295-12299. (Pubitemid 27203313)
38. Smith AR, Lambert PA, Hammond SM, and Jessup C (1975) The differing effects of cetyltrimethylammonium bromide and cetrimide B.P. upon growing cultures of Escherichia coli NCIB 8277. J Appl Bacteriol 38:143-149.
39. Sonişik M, Korkmaz A, Besim H, Karayalçin K, and Hamamci O (1998) Efficacy of cetrimide-chlorhexidine combination in surgery for hydatid cyst. Br J Surg 85: 1277. (Pubitemid 28430435)
40. Suzuki T, Murakami T, Iino R, Suzuki J, Ono S, Shirakihara Y, and Yoshida M (2003) F0F1-ATPase/synthase is geared to the synthesis mode by conformational rearrangement of epsilon subunit in response to proton motive force and ADP/ATP balance. J Biol Chem 278:46840-46846. (Pubitemid 37452264)
41. Umpleby HC and Williamson RC (1984) The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma. Ann R Coll Surg Engl 66:192-194.
42. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, and Mootha VK (2008) Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 26:343-351. (Pubitemid 351355127)
43. Warburg O (1930) The Metabolism of Tumours: Investigations from the Kaiser- Wilhelm Institute for Biology, Constable, London, UK.
44. Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr, and Chen LB (1987) Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci U S A 84:5444-5448.
45. Xu C, Bailly-Maitre B, and Reed JC (2005) Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115:2656-2664. (Pubitemid 41434389)
46. Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, and Liu FF (2006a) Potential use of alexidine dihydrochloride as an apoptosispromoting anticancer agent. Mol Cancer Ther 5:2234-2240. (Pubitemid 44530460)
47. Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, and Liu FF (2006b) Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res 12:5557-5569. (Pubitemid 44497274)
48. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, et al. (2005) Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11:8131-8144. (Pubitemid 41698758)
49. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73.
50. Zips D, Krause M, Hessel F, Westphal J, Brüchner K, Eicheler W, Dörfler A, Grenman R, Petersen C, Haberey M, et al. (2003) Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 23:3869-3876. (Pubitemid 37474336)